I'm hearing of another large wave of layoffs that were announced this week (also confirmed by LinkedIn posts). It looks like it might be hitting BID and maybe the Carlsbad site in particular. Can anyone provide more detail on who was impacted?
3 replies (most recent on top)
Thermo has a terrible reputation in the clinical research community. Porr quality output, high team turnover, etc. The Clario acquisition just means they purchased the company not its people. Learn from what they did to PPD. Destroyed a culture, ruined the reputation of a well-known and respected CRO. They keep pushing this CDMO model, but no one cares Thermo. Who wants to put all their eggs in your unstable backet?
Carlsbad and Rockford sites impacted by several Operations and R&D layoffs. Have heard it impacted more than just those sites...just don't know which exactly.
## Marc Casper's Stock Awards vs. Other Thermo Fisher Executives
Marc N. Casper, CEO of Thermo Fisher Scientific, received $22.67 million in equity awards in 2024, which constituted the majority of his $30.45 million total compensation. This includes stock options and performance-based stock units tied to company performance.
In comparison, other top executives received significantly lower equity compensation:
- Michel Lagarde, Executive VP and COO: $9.46 million in equity awards (total compensation: $12.78 million)
- Stephen Williamson, CFO: $8.08 million in equity awards (total compensation: $11.09 million)
- Gianluca Pettiti, Executive VP and President of Life Sciences: $8.67 million in equity awards (total compensation: $11.34 million)
- Frederick Lowery, Executive VP: $6.20 million in equity awards (total compensation: $8.53 million)
Casper’s equity awards are more than double those of any other executive, reflecting his role as CEO and the company’s pay-for-performance structure.